Welcome!

News Feed Item

Multiple Sclerosis Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Multiple Sclerosis Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256139/Multiple-Sclerosis-Global-Clinical-Trials-Review-H2-2014.html

Multiple Sclerosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Multiple Sclerosis Global Clinical Trials Review, H2, 2014" provides data on the Multiple Sclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Multiple Sclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Multiple Sclerosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Multiple Sclerosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Multiple Sclerosis 25
Subjects Recruited Over a Period of Time 35
Clinical Trials by Sponsor Type 36

Prominent Sponsors 37
Top Companies Participating in Multiple Sclerosis Therapeutics Clinical Trials 38
Prominent Drugs 40
Latest Clinical Trials News on Multiple Sclerosis 41
Jun 16, 2014: Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis 41
May 27, 2014: Bionure MS Drug Candidate Shows Positive Results for Myelin Repair in Cell Culture Assay 41
Clinical Trial Profiles 43
Clinical Trial Overview of Top Companies 43
Biogen Idec Inc. 43
Clinical Trial Overview of Biogen Idec Inc. 43
E. Merck KG 53
Clinical Trial Overview of E. Merck KG 53
Novartis AG 59
Clinical Trial Overview of Novartis AG 59
Teva Pharmaceutical Industries Limited 64
Clinical Trial Overview of Teva Pharmaceutical Industries Limited 64
Bayer AG 68
Clinical Trial Overview of Bayer AG 68

Sanofi 72
Clinical Trial Overview of Sanofi 72
GlaxoSmithKline plc 75
Clinical Trial Overview of GlaxoSmithKline plc 75
Acorda Therapeutics, Inc. 77
Clinical Trial Overview of Acorda Therapeutics, Inc. 77
Elan Corporation, plc 79
Clinical Trial Overview of Elan Corporation, plc 79
Pfizer Inc. 80
Clinical Trial Overview of Pfizer Inc. 80
Clinical Trial Overview of Top Institutes / Government 81
National Institute of Neurological Disorders and Stroke 81
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 81
Charite - Universitatsmedizin Berlin 83
Clinical Trial Overview of Charite - Universitatsmedizin Berlin 83
Tehran University of Medical Sciences 84
Clinical Trial Overview of Tehran University of Medical Sciences 84
U.S. Department of Veterans Affairs 85
Clinical Trial Overview of U.S. Department of Veterans Affairs 85
Oregon Health & Science University 86
Clinical Trial Overview of Oregon Health & Science University 86
The National Institute of Allergy and Infectious Diseases 87

Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 87
University of Washington 88
Clinical Trial Overview of University of Washington 88
St. Andrea Hospital Sapienza Rome University 89
Clinical Trial Overview of St. Andrea Hospital Sapienza Rome University 89
Imperial College London 90
Clinical Trial Overview of Imperial College London 90
Department of Health, UK 91
Clinical Trial Overview of Department of Health, UK 91
Five Key Clinical Profiles 92
Appendix 196
Abbreviations 196
Definitions 196
Research Methodology 197
Secondary Research 197
About GlobalData 198
Contact Us 198
Disclaimer 198
Source 198

List of Tables

Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21

Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Multiple Sclerosis Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Multiple Sclerosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Multiple Sclerosis Therapeutics, Global, Terminated Clinical Trials, 2014* 28
Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 35
Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 36
Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 37
Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 39
Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 40
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Biogen Idec Inc., 2014* 43
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by E. Merck KG, 2014* 53
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 59

Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Teva Pharmaceutical Industries Limited, 2014* 64
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 68
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 72
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 75
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Acorda Therapeutics, Inc., 2014* 77
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Elan Corporation, plc, 2014* 79
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 80
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 81
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Charite - Universitatsmedizin Berlin, 2014* 83
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 84
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 85

Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Oregon Health & Science University, 2014* 86
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014* 87
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014* 88
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by St. Andrea Hospital Sapienza Rome University, 2014* 89
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Imperial College London, 2014* 90
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Department of Health, UK, 2014* 91

List of Figures

Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18

Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 35
Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 36
Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 37
Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 38
Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 40
GlobalData Methodology 197

To order this report: Multiple Sclerosis Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256139/Multiple-Sclerosis-Global-Clinical-Trials-Review-H2-2014.html

_________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
Detecting internal user threats in the Big Data eco-system is challenging and cumbersome. Many organizations monitor internal usage of the Big Data eco-system using a set of alerts. This is not a scalable process given the increase in the number of alerts with the accelerating growth in data volume and user base. Organizations are increasingly leveraging machine learning to monitor only those data elements that are sensitive and critical, autonomously establish monitoring policies, and to detect...
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Consumers increasingly expect their electronic "things" to be connected to smart phones, tablets and the Internet. When that thing happens to be a medical device, the risks and benefits of connectivity must be carefully weighed. Once the decision is made that connecting the device is beneficial, medical device manufacturers must design their products to maintain patient safety and prevent compromised personal health information in the face of cybersecurity threats. In his session at @ThingsExpo...
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution and join Akvelon expert and IoT industry leader, Sergey Grebnov, in his session at @ThingsExpo, for an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.
Because IoT devices are deployed in mission-critical environments more than ever before, it’s increasingly imperative they be truly smart. IoT sensors simply stockpiling data isn’t useful. IoT must be artificially and naturally intelligent in order to provide more value In his session at @ThingsExpo, John Crupi, Vice President and Engineering System Architect at Greenwave Systems, will discuss how IoT artificial intelligence (AI) can be carried out via edge analytics and machine learning techn...
FinTechs use the cloud to operate at the speed and scale of digital financial activity, but are often hindered by the complexity of managing security and compliance in the cloud. In his session at 20th Cloud Expo, Sesh Murthy, co-founder and CTO of Cloud Raxak, showed how proactive and automated cloud security enables FinTechs to leverage the cloud to achieve their business goals. Through business-driven cloud security, FinTechs can speed time-to-market, diminish risk and costs, maintain continu...
When shopping for a new data processing platform for IoT solutions, many development teams want to be able to test-drive options before making a choice. Yet when evaluating an IoT solution, it’s simply not feasible to do so at scale with physical devices. Building a sensor simulator is the next best choice; however, generating a realistic simulation at very high TPS with ease of configurability is a formidable challenge. When dealing with multiple application or transport protocols, you would be...
Existing Big Data solutions are mainly focused on the discovery and analysis of data. The solutions are scalable and highly available but tedious when swapping in and swapping out occurs in disarray and thrashing takes place. The resolution for thrashing through machine learning algorithms and support nomenclature is through simple techniques. Organizations that have been collecting large customer data are increasingly seeing the need to use the data for swapping in and out and thrashing occurs ...
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
As many know, the first generation of Cloud Management Platform (CMP) solutions were designed for managing virtual infrastructure (IaaS) and traditional applications. But that’s no longer enough to satisfy evolving and complex business requirements. In his session at 21st Cloud Expo, Scott Davis, Embotics CTO, will explore how next-generation CMPs ensure organizations can manage cloud-native and microservice-based application architectures, while also facilitating agile DevOps methodology. He wi...